-

Hims & Hers Introduces 6-Month Wegovy® New Customer Offer

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS) today announced eligible customers can access 6 months of prescription-only Wegovy® at a new, affordable price, making proven obesity care and treatments more accessible, more affordable, and more connected for millions of Americans.

“We are always looking for long-term, sustainable ways to increase access to care for our customers,” said Andrew Dudum, CEO and co-founder of Hims & Hers. “This is another example of how we’re working together with the industry to bring people closer to the care and treatments they need.”

Starting today, new customers eligible for Wegovy® on the Hims & Hers platform can access their care for $549 per month for 6 months (for a limited-time only)1, ensuring customers have a longer window to access the affordable care they need. Included in that price is access to Hims & Hers’ world-class, holistic approach to weight loss, powered by today's technology. Hims & Hers will continue to offer access to its full breadth of weight loss treatment options, including other medications, oral kits, protein, nutrition kits, and clinically-backed care plans, all of which help customers start and sustain their health journey based on their needs, goals, and eligibility.

For more information, visit https://www.hims.com/novo-nordisk-collaboration.

About Hims & Hers Health, Inc

Hims & Hers is the leading health and wellness platform on a mission to help the world feel great through the power of better health. We believe how you feel in your body and mind transforms how you show up in life. That’s why we’re building a future where nothing stands in the way of harnessing this power. Hims & Hers normalizes health & wellness challenges—and innovates on their solutions—to make feeling happy and healthy easy to achieve. No two people are the same, so the company provides access to personalized care designed for results. For more information, please visit www.hims.com and www.forhers.com.

1 Promo ends 6/30/25. New Wegovy®, first-order customers only, paid up front in full. Savings vary by plan purchase. Discount based on Wegovy® average monthly retail price (w/o insurance). Standard rates resume after promo period: $649/mo (3-mo), $599/mo (6-mo). Auto-renews at standard rates unless canceled 2 days before billing. Rx required. Terms apply. Not available in all 50 states. Weight Loss by Hims & Hers is a holistic program that includes nutrition support, technological tools, and medications prescribed based on what your provider determines is medically appropriate and necessary for you. See website for full details, important safety information, and restrictions, including online provider consultation requirements.

Contacts

Press Contact
Abby Reisinger-Moley
press@forhims.com

Hims & Hers

NYSE:HIMS

Release Versions

Contacts

Press Contact
Abby Reisinger-Moley
press@forhims.com

More News From Hims & Hers

Hims & Hers Health, Inc. Prices Upsized $870.0 Million Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced the pricing of its offering of $870,000,000 aggregate principal amount of 0.00% convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced of...

Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Accelerate Global Expansion and Utilization of AI in Healthcare

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers” or the “Company”, NYSE: HIMS) today announced its intention to offer, subject to market and other conditions, $450 million aggregate principal amount of convertible senior notes due 2030 (the “notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Hims & Hers also expects to grant...

Hims & Hers Appoints AI Expert and Former President and CTO at Cruise as Chief Technology Officer

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the appointment of Mo Elshenawy, a proven technology executive with deep expertise in artificial intelligence and large-scale infrastructure, as the company’s new Chief Technology Officer. His appointment marks a key milestone as Hims & Hers accelerates its vision to build the next-generation healthcare platform, powered by AI and designed to deliver deeply pe...
Back to Newsroom